ABL Bio is closing in on another partnership with a global pharmaceutical company for its proprietary Grabody-B technology, a ...

Eli Lilly’s Mounjaro is the only dual drug on the market, targeting GLP-1 and GIP. Doctors say that Mounjaro is also more ...

The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and efficacy concerns, ...

Wegovy and Zepbound are two FDA-approved weight loss drugs. Learn how they compare in benefits, side effects, and more to ...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...

A new obesity drug that Eli Lilly is researching but hasn't approved is turning up online, even though it's not supposed to be available.

Tech giant Nvidia and pharma major Eli Lilly have announced a first-of-its-kind AI co-innovation lab focused on applying AI ...

Patients also have to deal with changes to their health insurance at the start of a new year, and more employers have ...

Eli Lilly and Company (NYSE:LLY) is one of the best long term growth stocks to buy according to hedge funds. On January 9, ...

Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor ...

Compounding pharmacy sues Eli Lilly and Novo Nordisk alleging antitrust violations to restrict compounded GLP-1 medication access and limit competition.

Drugmakers Eli Lilly and Novo Nordisk have been sued in Texas by a compounding pharmacy that alleges they are illegally ...